DMAC

Business Context and Reporting Period

Company: DiaMedica Therapeutics Inc. (DMAC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: DiaMedica is a clinical-stage biopharmaceutical company developing DM199, a recombinant human tissue kallikrein-1 (KLK1) protein, for the treatment of preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS). The company has no commercial revenue and relies on equity financing and interest income.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $4.8 million (31%) compared to the prior six-month period, driven primarily by higher R&D expenses.
• R&D Expense Growth: R&D expenses rose by $4.7 million year-over-year due to the expansion of the internal clinical team, global expansion of the ReMEDy2 trial, additional reproductive toxicity testing for the PE program, and increased share-based compensation.
• Liquidity Decline: Total cash, cash equivalents, and marketable securities decreased by approximately $16.4 million from December 31, 2025, to June 30, 2026, reflecting the burn rate of clinical operations.
• Share Count: Outstanding shares increased from 53.7 million to 53.9 million due to stock option exercises and RSU vesting.

Guidance, Outlook, and Risks

Clinical Progress and Outlook

• ReMEDy2 Trial (AIS): Enrollment is slower than expected due to staffing shortages, protocol logistics, and competition. As of August 1, 2026, enrollment reached 85% of the target for the interim analysis (200 participants). The interim analysis is now estimated to be completed in Q1 2027.
• PE/FGR Program: Part 1a of the investigator-sponsored trial in South Africa is complete with positive interim data showing blood pressure reduction. The company is preparing for a global Phase 2 trial in North America and the UK. However, the FDA has requested additional non-clinical reproductive toxicity data (rat PK study) before approving a U.S. IND application. This study is expected to complete in October 2026.

Liquidity and Capital Resources

Management expects current cash resources ($43.5 million) to fund planned operations for at least the next 12 months. However, the company anticipates needing substantial additional capital to complete clinical trials and regulatory activities. Future funding requirements depend on trial enrollment rates and regulatory timelines.

Key Risks

• Regulatory Uncertainty: Risk that FDA may not accept data from the South African trial or that additional non-clinical studies delay U.S. development.
• Enrollment Delays: Continued slow enrollment in the ReMEDy2 trial could delay the interim analysis and increase costs.
• Financing Needs: No assurance that additional equity or debt financing will be available on favorable terms or at all.

Investor Verification Checklist

• Cash Runway: Verify if the $43.5 million cash balance is sufficient to cover the projected burn rate through the anticipated Q1 2027 interim analysis, considering potential delays.
• FDA Feedback: Monitor the outcome of the rat PK study (due Oct 2026) and subsequent FDA acceptance for the U.S. PE IND application.
• ReMEDy2 Enrollment: Track the rate of site activation and patient enrollment to assess the likelihood of meeting the Q1 2027 interim analysis target.
• Dilution Risk: Review the remaining capacity under the At-The-Market (ATM) offering program ($86.2 million available) and potential future equity raises.
• Share-Based Compensation: Note the increasing impact of non-cash share-based compensation on operating expenses ($1.9 million for the six months ended June 30, 2026).